Valuation: enGene Therapeutics Inc.

Market Cap 128M 112M 105M 95.7M 179M 12.28B 180M 1.26B 487M 6.24B 481M 470M 20.09B P/E 2026 *
-1.05x
P/E 2027 * -1.22x
Enterprise Value -69.89M -60.94M -57.54M -52.25M -97.9M -6.71B -98.31M -689M -266M -3.41B -263M -257M -10.97B EV / Sales 2026 *
-
EV / Sales 2027 * -2.16x
Free-Float
99.9%
Yield 2026 *
-
Yield 2027 * -
1 week+6.11%
Current month+3.80%
1 month+7.91%
3 months+11.05%
6 months-73.51%
Current year-78.85%
1 week 1.84
Extreme 1.845
1.93
1 month 1.75
Extreme 1.75
1.95
Current year 1.4
Extreme 1.4
12.25
1 year 1.4
Extreme 1.4
12.25
3 years 1.4
Extreme 1.4
47.17
5 years 1.4
Extreme 1.4
47.17
10 years 1.4
Extreme 1.4
47.17
Manager TitleAgeSince
Chief Executive Officer 63 22/07/2024
Chief Tech/Sci/R&D Officer 55 24/04/2023
Director of Finance/CFO 48 16/07/2026
Director TitleAgeSince
Director/Board Member 57 08/08/2023
Director/Board Member 66 18/12/2023
Director/Board Member 66 15/05/2024
Date Insider Type Main position Quantity % Market Cap. Importance
16/7/26 Other

Interim Chief Business Officer

75,000 0.1120%
16/7/26 Other

Chief Financial Officer

0 0%
16/7/26 Other

Chief Financial Officer

170,800 0.2550%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+6.11%-71.99%-82.54% 128M
-0.31%+5.79%+47.13%+99.53% 70.88B
+0.39%+2.06%+39.38%+78.71% 62.49B
+5.36%+8.06%+32.49%+30.31% 26.34B
-3.21%-7.27%-17.10%+370.22% 26.21B
-2.64%-0.69%-0.17%-11.56% 24.13B
+0.71%+8.03%+25.03%-13.74% 20.72B
+2.12%-5.86%+161.58%+333.73% 15.69B
-0.22%+3.99%+45.54%+171.32% 14.46B
+0.73%+1.71%-5.51%+859.68% 14.24B
Average +0.30%+2.18%+25.64%+183.57% 27.53B
Weighted average by Cap. +0.19%+1.49%+35.71%+152.04%

Financials

2026 *2027 *
Net sales - 6.17M 5.38M 5.08M 4.61M 8.64M 592M 8.68M 60.86M 23.48M 301M 23.18M 22.66M 969M
Net income -124M -108M -102M -92.78M -174M -11.91B -175M -1.22B -472M -6.05B -466M -456M -19.48B -121M -106M -99.97M -90.78M -170M -11.65B -171M -1.2B -462M -5.92B -456M -446M -19.06B
Net Debt -198M -173M -163M -148M -277M -18.99B -278M -1.95B -753M -9.65B -743M -727M -31.06B -141M -123M -116M -106M -198M -13.56B -199M -1.39B -538M -6.89B -531M -519M -22.18B
Logo enGene Therapeutics Inc.
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
Employees
-
Date Price Change Volume
18/09/26 USD 1.910 0.00% 400,979
17/09/26 USD 1.910 0.00% 637,548
16/09/26 USD 1.910 +1.06% 579,256
15/09/26 USD 1.890 +1.07% 618,745
14/09/26 USD 1.870 +3.89% 460,523
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
1.910USD
Average target price
3.286USD
Spread / Average Target
+72.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ENGN Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!